Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.

<h4>Background</h4>Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs.<h4>Objectives</h4>The aim of this study was to evaluate th...

Full description

Bibliographic Details
Main Authors: Haiying Ding, Wenxiu Xin, Yinghui Tong, Jiao Sun, Gaoqi Xu, Ziqi Ye, Yuefeng Rao
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0238536

Similar Items

Similar Items